Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2010

01.07.2010 | Original Article

Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis

verfasst von: Su Jin Lee, Jeeyun Lee, Ho Yeong Lim, Won Ki Kang, Chel Hun Choi, Jeong-Won Lee, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun, Young Suk Park

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A recent study demonstrated that colorectal cancer (CRC) with ovarian metastases was less responsive to chemotherapy compared with extraovarian metastases. Hence, the ovary may actually represent a “sanctuary” for metastatic cells from CRC. The aim of the study was to investigate the impact of ovarian metastatectomy on survival of CRC patients with ovarian metastasis.

Methods

Between 1996 and 2008, 83 CRC patients underwent an oophorectomy. For the historical control, 47 CRC patients with ovarian metastasis without resection were included in the analysis.

Results

The median age was younger (48 years) in the oophorectomy group compared with the historical control (54 years; P = 0.012). The proportion of synchronous metastasis was higher in the oophorectomy group than in the control group (57 vs. 30%; P = 0.003). After a median follow-up duration of 60.8 months (range of 7.4–169.7 months), the median OS was significantly longer in the oophorectomy group (28.1 vs. 21.2 months, oophorectomy vs. non-oophorectomy; P = 0.038). For ovary-specific survival (date of ovarian metastasis diagnosis to death), CRC patients with an oophorectomy showed a significantly more favorable survival rate than the control group (20.8 vs. 10.9 months; P < 0.001). In univariate analyses, oophorectomy (P = 0.038), unilaterality of ovarian metastasis (P = 0.032), metastasis confined to ovaries (P < 0.001), normal CEA level (P < 0.001), good performance status (P = 0.001), palliative chemotherapy (P = 0.001), and primary disease resection (P = 0.005) were identified as significantly good prognostic factors for overall survival. The oophorectomy, chemotherapy, metastasis confined to ovaries, normal CEA level, and good performance status retained statistical significance at the multivariate level (P = 0.003, P = 0.004, P = 0.005, P = 0.015, and P = 0.029, respectively).

Conclusions

Based on this retrospective analysis, the ovarian metastatectomy significantly prolonged survival in CRC patients with ovarian metastases. The potential role of an ovarian metastatectomy in the management of CRC should be prospectively studied.
Literatur
1.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed
2.
Zurück zum Zitat Cutait R, Lesser ML, Enker WE (1983) Prophylactic oophorectomy in surgery for large-bowel cancer. Dis Colon Rectum 26:6–11CrossRefPubMed Cutait R, Lesser ML, Enker WE (1983) Prophylactic oophorectomy in surgery for large-bowel cancer. Dis Colon Rectum 26:6–11CrossRefPubMed
3.
Zurück zum Zitat Goere D, Daveau C, Elias D, Boige V, Tomasic G, Bonnet S, Pocard M, Dromain C, Ducreux M, Lasser P, Malka D (2008) The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol 34:1335–1339PubMed Goere D, Daveau C, Elias D, Boige V, Tomasic G, Bonnet S, Pocard M, Dromain C, Ducreux M, Lasser P, Malka D (2008) The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol 34:1335–1339PubMed
4.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed
5.
Zurück zum Zitat Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214CrossRefPubMed Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214CrossRefPubMed
6.
Zurück zum Zitat Huang PP, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698CrossRefPubMed Huang PP, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698CrossRefPubMed
7.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed
8.
Zurück zum Zitat Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553–4560CrossRefPubMed Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553–4560CrossRefPubMed
9.
Zurück zum Zitat Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Kim YI (2008) Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg 393:13–19CrossRefPubMed Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Kim YI (2008) Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg 393:13–19CrossRefPubMed
10.
Zurück zum Zitat Liang JT, Lai HS, Wu CT, Huang KC, Lee PH, Shun CT (2007) Laparoscopic prophylactic oophorectomy plus N3 lymphadenectomy for advanced rectosigmoid cancer. Ann Surg Oncol 14:1991–1999CrossRefPubMed Liang JT, Lai HS, Wu CT, Huang KC, Lee PH, Shun CT (2007) Laparoscopic prophylactic oophorectomy plus N3 lymphadenectomy for advanced rectosigmoid cancer. Ann Surg Oncol 14:1991–1999CrossRefPubMed
11.
Zurück zum Zitat Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM (2004) Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 93:87–91CrossRefPubMed Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM (2004) Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 93:87–91CrossRefPubMed
12.
Zurück zum Zitat Poston G, Adam R, Vauthey JN (2006) Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol 24:2702–2706CrossRefPubMed Poston G, Adam R, Vauthey JN (2006) Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol 24:2702–2706CrossRefPubMed
13.
Zurück zum Zitat Taylor AE, Nicolson VM, Cunningham D (1995) Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment. Br J Cancer 71:92–96PubMed Taylor AE, Nicolson VM, Cunningham D (1995) Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment. Br J Cancer 71:92–96PubMed
14.
Zurück zum Zitat Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed
15.
Zurück zum Zitat Young-Fadok TM, Wolff BG, Nivatvongs S, Metzger PP, Ilstrup DM (1998) Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. Dis Colon Rectum 41:277–283 discussion 283-5CrossRefPubMed Young-Fadok TM, Wolff BG, Nivatvongs S, Metzger PP, Ilstrup DM (1998) Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. Dis Colon Rectum 41:277–283 discussion 283-5CrossRefPubMed
16.
Zurück zum Zitat KJ Yum JH, Kim YB et al (1999) Analysis of 38 cases of metastatic cancer to ovary. J Korean Cancer Assoc 31:575–581 KJ Yum JH, Kim YB et al (1999) Analysis of 38 cases of metastatic cancer to ovary. J Korean Cancer Assoc 31:575–581
Metadaten
Titel
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
verfasst von
Su Jin Lee
Jeeyun Lee
Ho Yeong Lim
Won Ki Kang
Chel Hun Choi
Jeong-Won Lee
Tae-Joong Kim
Byoung-Gie Kim
Duk-Soo Bae
Yong Beom Cho
Hee Cheol Kim
Seong Hyeon Yun
Woo Yong Lee
Ho-Kyung Chun
Young Suk Park
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1150-2

Weitere Artikel der Ausgabe 2/2010

Cancer Chemotherapy and Pharmacology 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.